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ABSTRACT 
Objective: The objective of the present study is to evaluate the effect of Phthalate analogues of diclofenac in Freund’s complete adjuvant (FCA) 
induced Arthritis in the rat. 
Methods: Twenty four female albino wistar rats were enrolled in this study and are divided into 4 groups (six each). The groups were designed as 
follows: Group I: vehicle control, Group II: arthritic control, Group III: diclofenac treated, Group IV: phthalate analogue of diclofenac treated. Various 
assessments such as anti-arthritic activity, biochemical estimations, haematological parameters, ulcerogenesis, radiological and histopathological 
studies were evaluated. 
Results: Arthritic control group exhibited significant increase in the level of paw volume, arthritic score (p<0.0001), Serum glutamic pyruvic transaminase 
(SGPT) (p<0.001), Serum glutamic oxaloacetic transaminase (SGOT) p<0.01), rheumatoid arthritis factor, C-reactive protein (CRP), White Blood Cells (WBC), 
Creatinine and uric acid and a significant decrease in Red Blood Cells (RBC). Increased swelling of joints, bony destruction and profound ulceration were 
observed in the Arthritic control group. All these conditions were reversed in diclofenac and phthalate analogue of diclofenac groups. 
Conclusion: We conclude that phthalate analogue of diclofenac shows potent anti-arthritic activity with milder ulceration when compared to 
diclofenac treatment.  
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Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune 
disease with the main clinical manifestation of systemic complications 
including synovial inflammation, joint lesion and bone damage [1]. In 
RA, pannus is rich in secretion of activated macrophages and other 
inflammatory mediators, resulting in the destruction of tissues when 
compared to normal synovial fluid, which is essentially a cellular [2]. 
One of the most important groups of mediators in RA is cytokines. The 
most prominent of these include TNF, IL-1, and IL-6, which are 
released in the synovial microenvironment [3, 4]. Rheumatoid arthritis 
is also characterized by the presence of autoantibodies known as 
rheumatoid factors (RF) and anti-citrullinated peptide antibodies 
(ACPA). Therefore RA synovial fluid is abundant in neutrophils, 
macrophages, T lymphocytes, autoantibodies and dendritic cells. 
Chondrocytes secrete proteolytic enzymes that lead to destruction of 
articular cartilage causing bone deformity and loss of joint function. It 
is thought that costimulation of both humoral and cellular immunity 
may contribute to the pathology of the disease [5]. 
RA affects all the races, where the female population is affected 
three times more than the male population. The cause of RA is still a 
mystery. The management of RA includes Nonsteroidal anti-
inflammatory Drugs (NSAIDs), Glucocorticoids, Disease-Modifying 
Anti-Rheumatic Drugs (DMARDs) and Biologic agents [6]. Among the 
most popular NSAIDs worth mentioning is diclofenac ranked 30th 
among the top 200 drugs with respect to new prescriptions. 
Diclofenac sodium has been demonstrated to have antipyretic 
activity and to be an effective analgesic in rats and mice and in 
therapeutic trials in patients with rheumatoid arthritis, 
osteoarthritis or pain of varying origin [7]. Despite the intensive 
research that has been aimed at the development of diclofenac, their 
clinical usefulness is still restricted by their gastrointestinal side 
effects like gastric irritation, ulceration, bleeding, perforation and 
also cardiovascular complications. Hence, the scope of the research 
widens for the newer, effective and safer alternative medicine. 
Gastrointestinal (GI) toxicity is attributed to direct contact of free 
carboxylic acid (–COOH) moiety present on diclofenac sodium with GI 
mucosal cells [7]. Hence as an alternative approach, in order to avoid 
major GI side effects, we have focused our research work on Synthetic 
derivatization based upon chemical modification of diclofenac structure. 
Therefore we have attempted to design phthalate analogue of diclofenac 
by replacing free acidic group on diclofenac structure by the most potent 
less acidic heterocyclic ligand–phthalate moiety. The latter showed 
negligible GI toxicity, due to very good selective interactive energies with 
cyclooxygenase-2 (COX-2) when compared to that of diclofenac sodium 
[8]. Hence the present study was therefore aimed to synthesize and 
evaluate phthalate analogue of diclofenac and was designed to 
investigate whether the synthesized compound exerts an ameliorative 
effect on arthritis in rats exposed to Freund’s complete adjuvant (FCA) 
and to ascertain its potential mechanism with less ulcerogenicity. 
MATERIALS AND METHODS 
Selection and synthetic scheme of the phthalate analogue of 
diclofenac 
Diclofenac sodium was hydrolyzed using concentrated sulphuric 
acid to convert salt to acid. The obtained intermediate was refluxed 
for 22 h with absolute alcohol and concentrated sulphuric acid. The 
obtained ethyl ester reaction mixture was sodium bicarbonate 
solution and recrystalised with methanol. The recrystalised ester 
was refluxed with hydrazine hydrate along with absolute alcohol for 
22 h. Finally the precipitated mixture was filter dried and 
recrystalised from methanol. Yield: 87.44%, mp: 112 °C. 
Acute oral toxicity studies of phthalate analogue of diclofenac–
OECD 423 guideline 
Acute oral toxicity studies were performed using a phthalate 
analogue of diclofenac at the dose level of 300 mg/kg orally in mice. 
Animals 
Healthy adult female Albino Wister Rats (150-200 g: 24 rats) were 
obtained from Swamy Vivekananda College of Pharmacy, Tiruchengodu. 
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All animals used in this study were handled with Indian National Science 
Academy Guidelines and the animal experiments were performed 
according to the guidelines prescribed by CPCSEA. The study protocol 
was approved by the Institutional Animal Ethics Committee (Reg. 
No.889/PO/ac/05/CPCSEA/dated 9th November 2011). 
Study design 
24 Albino Wistar rats were used for this study. They were randomly 
divided into 4 groups of each of 6 rats. Thirty minutes after 
administration of vehicle/drug, arthritis was induced by sub plantar 
injection of0.1 ml of 0.5% Freund’s complete adjuvant (FCA) into the 
tibia tarsal joint. Group-I animal receives only distilled water, Group-
II animal receives 0.1 ml of 0.5% Freund’s complete adjuvant, 
Group-III animal receives0.1 ml of 0.5% Freund’s complete adjuvant 
along with Diclofenac 10 mg/kg/p. o for 21 d, Group-IV receives 0.1 
ml of 0.5% Freund’s complete adjuvant along with phthalate 
analogue of Diclofenac 30 mg/kg/p. o for 21 d [9]. 
Anti-arthritic activity of phthalate analogue of diclofenac was 
evaluated on paw volume, arthritis score on day 5, 10, 15 and day 
21. Moreover body weights of animals were monitored regularly 
during the course of the experiment. On day 21, blood was 
withdrawn by a retro-orbital puncture for assessment of 
haematological parameters and animals were sacrificed under light 
ether anaesthesia to study histopathology of joints. 
Arthritis score 
Morphological feature of arthritis was monitored according to the extent 
of erythema and oedema of the joints, using the criteria as follows: 
normal paw = 0, mild swelling and erythema of digits = 1, moderate 
swelling and erythema of digits = 2, severe swelling and erythema of 
digits = 3, gross deformity and inability to use limbs = 4 [10, 11]. The 
scores for each paw were then added to get the total arthritic score. 
Paw volume 
The left hind paw volume of all animal was measured just before 
Freund’s complete adjuvant injected at different time intervals till 21 d 
using Plethysmography. The change in paw volume was measured as the 
difference between the final and initial paw volumes [11, 12]. 
Haematological, biochemical, radiological studies 
The haematological parameters like RBC, WBC, PCV and HB count 
were assessed using chesbrough and McArthur. The hemoglobin count 
was determined by acid haematin method [13]. On day 21, blood was 
withdrawn by retro-orbital puncture and serum was used for 
estimation of biochemical markers like SGOT, SGPT, ALP, RA factor, 
Creatinine and serum uric acid [14, 15]. Radiographs were taken for 
the hind paw of all groups and examined for soft tissue swelling, bony 
erosions and narrowing of spaces between the joints [16-18]. 
Determination of the ulcerogenic effect 
The animals were sacrificed on 22nd day and the stomach is 
dissected out. The contents of the stomach are drained into a 
graduated centrifuge tube and their activity determined by titration 
with 0.1N NaoH. The stomach was opened along its greater 
curvature and its inner surface examined for ulceration with the 
binocular microscope [19]. 
The ulcer index is calculated and the ulcer severity graded as 
mentioned below:  
0 = Normal coloured stomach, no ulcer 
0.5 = Red colouration 
1 = Spot ulcers 
1.5 = Haemorrhagic streaks 
2 = Ulcers 
3 = Perforation 
Histological analysis 
The animals were sacrificed on day 21 by cervical dislocation. Ankle 
joints were separated from the hind paw, weighed and immersed in 
10% buffered formalin for 24 h followed by decalcification in 5% 
formic acid, processed for paraffin embedding sectioned at 5-
thickness. The sections were stained with haematoxylin and eosin 
and evaluated under a light microscope [20]. 
Statistical analysis 
The statistical comparison was made between arthritic control and 
treated group. They were analyzed by one way ANOVA followed by 
Dunnet’s comparison test. The level of significance was at p<0.05.16. 
RESULTS 
Effect of phthalate analogue of diclofenac changes in acute oral 
toxicity studies 
The phthalate analogue of diclofenac does not produce any toxic 
symptoms or mortality up to dose level of 300 mg/kg orally in mice 
and hence the drug was considered safe for further pharmacological 
screening. As per OECD-423 1/10 (30 mg/kg) of phthalate analogue 
of diclofenac was used for future pharmacological screening. No 
lethal toxic reaction was observed till the end of 21 d. 
Effect of phthalate analogue of diclofenac on an arthritic score 
In this study, there was a significant increase in arthritic score in the 
arthritic control group when compared to vehicle control. On the 
day of 5th, 10th, 15th and 21st days, arthritic control group showed 
significant (p<0.0001) increase when compared to phthalate 
analogue of diclofenac and diclofenac group (table 1). 
Effect of phthalate analogue of diclofenac on change in paw volume 
There was a significant (p<0.001) increase in paw volume in all FCA 
(Freund’s complete adjuvant) administered group compared to 
phthalate analogue of diclofenac and diclofenac treated group. This 
showed biphasic response where there was small change in 
decrease in paw volume from 10 to 15 d. Hence this change was no 
significant. Treated group (Group III and IV) significantly (p<0.01, 
p<0.001) showed decreased paw volume when observed till end of 
study. There was significant change in paw volume of phthalate 
analogue of diclofenac and diclofenac treated group (table 2) 
Effect of phthalate analogue of diclofenac on haematology 
estimation 
The haematological parameters were observed in which WBC and 
PCV showed significant (p<0.001) increase only group II (arthritic 
control) when compared to other groups. RBC and HB showed 
decreased (p<0.0001) value in group II. (table 3) 
Effect of phthalate analogue of diclofenac on biochemical 
estimation 
In this study, group II showed a significant (p<0.0001) increase 
when compared to group III and IV. SGPT and SGOT in group II is 
significantly increased (p<0.001, p<0.01) when compared to 
phthalate analogue of diclofenac and diclofenac treated group. ALP, 
CRP and RA factor were also increased in group II and showed the 
significant value (p<0.001) (table 4) 
Effect of phthalate analogue of diclofenac on radiographic studies 
In adjuvant-induced arthritic rat (group II), soft tissue swelling along 
with narrowing of joints spaces were observed which implies bony 
destruction in arthritic condition. The standard drug diclofenac 10 
mg/kg treated group have prevented this bony destruction and also 
there is no swelling of joint (fig. 2: A, B, C, D). 
Effect of phthalate analogue of diclofenac on anti-ulcer activity 
Group I has showed normal colour stomach and scored as 0. Group II 
(negative control) showed major effect and the score is found to be 
1. Diclofenac treated (Group III) group has showed gastric mucosal 
damage compared to group II and the score is 2. Group IV phthalate 
analogue of diclofenac with inducer has showed less ulcer activity 
compared to group II and the score is 3 (fig. 2: A, B. C, D) 
Effect of phthalate analogue of diclofenac on histopathological 
study 
The histopathological study has shown significant prevention against 
bony destruction by soft tissue swelling are narrowing of joint spaces 
when compared with an arthritic control group (fig. 3: A, B, C, D) 
Manimekalai et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 12, 40-45 
42 
Table 1: Effect of phthalate analogue of diclofenac on arthritic score 
Group Arthritic score 
5 days 10 days 15 days 21 days 
Group I-Vehicle control 1.07±0.01 1.48±0.06 1.50±0.23 1.62±0.24 
Group II-(FCA) 1.33±0.01 3.07±0.19a** 3.30±0.21a** 3.91±0.04a*** 
GroupIII(FCA+diclofenac) 1.56±0.17 2.98±0.07a*** 2.83±0.13a*** 2.67±0.22b*** 
GroupIV(FCA+phthalate analogueof diclofenac) 1.61±0.03 2.63±0.18b*** 2.42±0.21b*** 2.34±0.405b*** 
Values are expressed as mean±SEM, n=6 Symbols represent statistical significance: *** p<0.001, **p<0.01, *p<0.5: a-Group I Vs II, III and IV b-Group 
II Vs II, IV. 
 
Table 2: Effect of phthalate analogue of diclofenac on change in paw volume 
Group Paw volume (ml) 
5 days 10 days 15 days 21 days 
Group I-Vehicle control 1.01±0.03 1.91±0.07 1.86±0.30 1.61±0.07 
Group II (FCA) 1.23±0.22 3.44±0.28a* 3.77±0.19 3.83±0.16a** 
GroupIII(FCA+diclofenac) 1.30±0.05 2.92±0.36b* 2.85±0.10 2.67±0.30 
GroupIV(FCA+phthalateanalogueofdiclofenac) 1.44±0.23 2.65±0.167a*** 2.40±0.30 2.33±0.20b** 
Values are expressed as mean±SEM, n=6, Symbols represent statistical significance: *** p<0.001, **p<0.01, *p<0.5: a-Group I Vs II, III, IV. b-Group II 
Vs, III and IV 
 
Table 3: Effect of phthalate analogue of diclofenac on Haematology parameters 
Group RBC (1x103/µl) WBC (1x103/µl) HB (g/dl) PCV (%) 
GroupI(Vehicle control) 5.05±0.21 7.460±0.27 14.91±0.81 40.07±0.98 
Group II (FCA) 2.70±0.18a** 17.92±1.55a*** 9.095±0.39a** 45.32±3.65a*** 
GroupIII(FCA+diclofenac) 4.37±0.14b*** 11.97±0.83 15.48±0.17 38.43±2.75 
GroupIV(FCA+phthalate analogue of 
Diclofenac) 
4.150±0.24 10.35±0.53 14.42±0.88 39.47±1.033 
Values are expressed as mean±SEM, n=6 Symbols represent statistical significance: *** p<0.001, **p<0.01, *p<0.5: a-Group I Vs II, III,IV. b-Group II 
Vs I, III and IV 
 
Table 4: Effect of phthalate analogue of diclofenac on biochemical parameters 
Group Creatinine Uric acid SGPT SGOT ALP 
Group I (Vehicle control) 0.393±0.09 1.500±0.18 25.50±0.76 33.67±3.49 68.33±16.02 
Group II (FCA) 1.47±0.22a*** 5.93±0.08a*** 54.10±3.25a*** 55.40±1.15a** 217.5±19.4a*** 
Group III (FCA+diclofenac) 0.270±0.06b*** 5.300±0.09b** 26.23±0.92b*** 35.00±2.22b** 86.50±11.76b* 
Group IV (FCA+phthalate 
analogue of diclofenac) 
0.500±0.30b*** 4.25±0.52 23.83±2.24b*** 33.67±2.07b** 70.33±8.65b** 
Values are expressed as mean±SEM, n=6, Symbols represent statistical significance: *** p<0.001, **p<0.01, *p<0.5: a-Group I Vs II,III,IV. b-Group II 
Vs, III and IV 
 
 
Fig. 1: Effect of phthalate analogues of diclofenac on radiography 
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Fig. 2: Effect of phthalate analogue of diclofenac on anti-ulcer activity A-Group I, B-Group II, C-Group III and D-Group IV 
 
 
Fig. 3: Effect of diclofenac and phthalate analogue of diclofenac on histological analysis, A-Group I, B-Group II, C-Group III and D-Group IV  
 
DISCUSSION 
Non-steroidal anti-inflammatory drugs, often referred to as NSAIDs, 
are assumed to be well tolerated and are widely used as initial therapy 
for anti-arthritis. Everyone is familiar with these types of drugs with 
millions using them for pain. The gastrointestinal side effect associated 
with all traditional NSAID’s is mainly due to the presence of free 
carboxylic acidic group. Hence in the present study the–COOH group of 
diclofenac was replaced by the substitution of phthalate group to 
reduce its side effect and to potentiate RA activity. 
The phthalate analogue of diclofenac does not produce any toxic 
symptoms or mortality up to the dose level of 300 mg/kg orally in 
mice and hence, the drug was considered safe for further 
pharmacological screening. Therefore 1/10 of the dose (30 mg/kg) 
was selected for in vivo study. 
In the present study, Freund’s complete a djuvant was used for the 
induction arthritis. This model is widely used to study the pathogenesis 
of rheumatoid arthritis for testing therapeutics and this model is 
characterized by a very rapid erosive disease. The bacterial 
peptidoglycan and muramyl dipeptide present in the FCA are 
responsible for the induction of adjuvant arthritis [21]. The 
determination of paw swelling is an apparently simple, sensitive and 
quick procedure for evaluating the degree of inflammation and assessing 
of therapeutic effects of drugs. In the present study, the rat was selected 
as an animal model since they develop a chronic swelling in multiple 
joints with an influence of inflammatory cells and followed by erosion of 
cartilage in joints and destruction of bones. The rat model is a close 
resemblance to rheumatoid arthritis of human beings [22]. 
As one of the major factors in assessing the degree of inflammation 
and curative efficacy of drug is hind paw volume and this was 
measured using plethysmography in the present study. FCA group 
showed increased paw volume due to stimulation of inflammatory 
cytokines in cell-mediated immunity when compared control group. 
Phthalate analogue of diclofenac treatment group shows 
significantly inhibitory effect on hind paw swelling due to reduced 
inflammatory response when compared to diclofenac group [23]. 
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In the present study, the reduction in RBC and haemoglobin level in the 
adjuvant induced arthritic control rats denotes the anaemic condition. 
These decreased levels of RBC, and HB (haemoglobin) was significantly 
increased by phthalate analogue of diclofenac and diclofenac treatment. 
The increased levels of WBC and packed cell volume (PCV) in the 
adjuvant induced arthritic control rats due to the stimulation of immune 
system against the invading pathogens. These increased levels of WBC 
and packed cell volume (PCV) was significantly decreased by phthalate 
analogue of diclofenac and diclofenac treatment. All these symptoms 
indicate an anemic condition, which is a common diagnostic feature in 
patients with chronic arthritis. 
In this study, RA factor in FCA group shows significant increase due 
to formation of immune complexes that contribute to the progress of 
rheumatoid arthritis. The phthalate analogue of diclofenac and 
diclofenac treatment group showed significant decrease in RA factor 
when compared to FCA control (Mali SM et al., 2011). And CRP level 
of FCA group is increased due to plasma level increase and tissue 
damage. The Phthalate analogue of diclofenac revert this increased 
level when compared to diclofenac group [24]. 
In this study, serum SGPT, SGOT and ALP was raised in Arthritic rat 
due to liver and spleen impairment, whereas in phthalate analogue 
of diclofenac the level is significantly lowered due to abnormal high 
level of plasma when compared to diclofenac group. From the 
obtained results it was shown that creatinine and uric acid levels 
were increased due to damage of renal tubules that leads to massive 
accumulation. The Phthalate analogue of diclofenac shows 
significant decrease in creatinine and uric acid levels when 
compared to diclofenac group. 
The histopathology analysis identifies the ability of the bones to re-
form upon treatment with diclofenac 10 mg/kg and Phthalate 
analogue of diclofenac 30 mg/kg p. o have that shows significant 
prevention against bony destruction, tissue swelling and narrowing 
of joint spaces when compared with complete Freund’s adjuvant 
control group. 
Radiography changes in rheumatoid arthritis condition are useful 
markers which indicate the severity of the disease. Soft tissue 
swelling is earlier radiographic sign, whereas prominent 
radiographic changes like bony erosion and narrowing of joint 
spaces can be observed only in the developed stages of arthritis. In 
adjuvant induced arthritic rat (group II), soft tissue swelling along 
with narrowing of the joint spaces were observed which implies the 
bony destruction in arthritic condition. The test compound phthalate 
analogue of diclofenac has prevented this bony destruction and also 
there is no swelling of the joint. 
In ulcerogenecity of FCA Group shows mild ulceration with ulcer 
score-2 when compared to control group. Diclofenac group produce 
more ulceration with ulcer score-3 when compared to control. 
Phthalate analogue of diclofenac group shows very less incident of 
ulceration with ulcer score-1 when compared to control group. 
The overall findings of the current study reveal that Phthalate 
analogue of diclofenac attenuates FCA induced arthritis in rats. 
CONCLUSION 
In conclusion, replacement of-COOH group of diclofenac and 
addition of phthalic anhydride group to produce phthalate analogue 
of diclofenac acts as potential ligand for anti-arthritis with less 
gastro intestinal toxicity. Further clinical data are required to 
explore this synthesised analogue of diclofenac as potential ligand 
for improving the status of RA patients. 
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